Form 4: Merit Medical Director Receives RSU Grant
Statement of Changes in Beneficial Ownership
Director Thomas J. Gunderson was granted 3,457 restricted stock units under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan.
Summary
- Director Thomas J. Gunderson acquired 3,457 restricted stock units (RSUs) on May 18, 2026.
- The RSUs were granted under the Merit Medical Systems, Inc. 2026 Equity Incentive Plan.
- The grant is subject to continued service to the issuer through the vesting date of May 3, 2027.
- Following this transaction, the reporting person's total beneficial ownership is 39,491 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
- Retention of key leadership through a multi-year vesting schedule.
Negatives
- None identified; this is a standard equity compensation disclosure.
Risks
- Vesting of the RSUs is contingent upon continued service to the issuer through May 3, 2027.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the medical device sector, intended to align board incentives with long-term company performance.
Comparison to Industry Standards
- The use of RSU grants with multi-year vesting is consistent with standard executive and director compensation packages among mid-cap medical technology companies.
- The reporting of these transactions via Form 4 complies with standard SEC regulatory requirements for publicly traded entities.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Appointment of Brian G. Lloyd, Raul Parra Jr., and Matthew C. Fleming as attorneys-in-fact for SEC filings. | 10/03/2025 | Standard administrative update to facilitate timely regulatory compliance. |
Stakeholder Impact
- Shareholders: Minimal impact; reflects standard director compensation practices.
Next Steps
- Vesting of the 3,457 RSUs on May 3, 2027, subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 05/24/2020 | Commencement of vesting for initial tranche of non-qualified stock options. |
| 05/31/2020 | Commencement of vesting for second tranche of non-qualified stock options. |
| 10/03/2025 | Execution date of the Power of Attorney for SEC filings. |
| 05/18/2026 | Date of the reported RSU grant transaction. |
| 05/24/2026 | Expiration date for the first tranche of non-qualified stock options. |
| 05/31/2026 | Expiration date for the second tranche of non-qualified stock options. |
| 05/03/2027 | Vesting date for the newly granted 3,457 RSUs. |
Keywords
Merit Medical Systems, MMSI, Form 4, Director Compensation, Equity Incentive Plan, Insider Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.